Newsfeeds - Spark Newswire

1 minute read

Xenon Receives $15M Regulatory Milestone Under Epilepsy Pact With Neurocrine

Today, 5:51 AM

Xenon Pharmaceuticals Inc's (NASDAQ: XENE) collaboration to develop treatments for epilepsy with Neurocrine Biosciences Inc (NASDAQ: NBIX) achieved a regulatory milestone,

NBIX

3 minute read

Wednesdays With Wedbush: Analyst Laura Chico On The State Of Biotech

By Joel Elconin

Today, 5:51 AM

For most issues in the biotech sector, it was a rough 2021, especially when compared to the gains in the S&P 500 index, Wedbush's Laura Chico said Wednesday on "PreMarket Prep Plus." Chico, the senior vice president of biotech equity research at the analyst firm, said she attributes the underperformance to a few factors.

KDNY

7 minute read

Xenone Pharma Highlights Presentation Of Added Positive Data From Phase 2b ‘X-TOLE’ Trial At Annual Meeting Of American Epilepsy Society: Data Showed All Primary, Secondary Endpoint Reductions Were Statistically Significant

By Benzinga Newsdesk

Today, 5:51 AM

Topline Data Showed All Primary and Secondary Seizure Reduction Endpoints Statistically Significant Across All Dose Groups, with p-value of <0.001 for 20 mg and 25 mg Dose Groups Results from New Sub-Analyses

XENE

3 minute read

Xenon Pharma Offers Update On Its Neurology Programs At Annual Meeting Of American Epilepsy Society

By Benzinga Newsdesk

Today, 5:51 AM

Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neurology-focused biopharmaceutical company, today announced that it will provide updates on its proprietary, neurology programs at the Annual Meeting of the American Epilepsy

XENE

2 minute read

The Week Ahead In Biotech (Nov. 28-Dec. 4): FDA Decisions For VBI Vaccines, BeyondSpring, CTI Biopharma And Merck Take The Spotlight In A Light Calendar Week

By Shanthi Rexaline

Today, 5:51 AM

Biotech stocks advanced in the week ending Nov. 26, as a late-week surge on the back of news about a new COVID-19 variant, named Omicron, helped mitigate the losses notched earlier in the holiday-shortened week.

AADI

1 minute read

SVB Leerink Maintains Outperform on Xenon Pharmaceuticals, Raises Price Target to $40

By Benzinga Newsdesk

Today, 5:51 AM

SVB Leerink analyst Marc Goodman maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperform and raises the price target from $34 to $40.

XENE

18 minute read

Earnings Scheduled For November 10, 2021

By Benzinga Insights

Today, 5:51 AM

Companies Reporting Before The Bell • LumiraDx (NASDAQ:LMDX) is projected to report quarterly loss at $0.24 per share on revenue of $94.32 million.

AACG

7 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For October 28, 2021

By Benzinga Insights

Today, 5:51 AM

AGNC

2 minute read

Shares of Xenon Pharmaceuticals Inc. Have Risen Above Previous 52-Week High

By InvestorBrandNetwork

Today, 5:51 AM

Shares of Xenon Pharmaceuticals Inc. (NASDAQ: XENE) traded at a new 52-week high today of $34.80.

XENE

4 minute read

The Week Ahead In Biotech (Oct. 10-16): Avadel FDA Decision, Conference Presentations And IPOs Take Center Stage

By Shanthi Rexaline

Today, 5:51 AM

Biotech stocks retreated in the week ending Oct. 8, extending losses for the third straight week. Some of the selling in the space was due to money moving out of defensive stocks and into risky bets amid the broader market strength.

AEON